Drug Interactions with Commonly Used Immunosuppressive Agents

Medical Care of the Liver Transplant Patient, 3E

Volumn , Issue , 2007, Pages 522-535

  Killenberg, Paul G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889615151     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470751541.ch30     Document Type: Chapter

References (41)

1. First M, Schroeder T, Weiskittel P, et al. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet 1982;1(8673):1198–1201.
2. Duvoux C, Cherqul D, DiMartino V, et al. Nicardipine as antihypertensive therapy in liver transplant recipients: Results of long-term use. Hepatology 1997;25:430–433.
3. Grebenau M. Sandimmune1 (cyclosporine) drug interactions. East Hanover, NJ: Sandoz Pharmaceuticals, 1994.
4. Yee G, McGuire T. Pharmacokinetic drug interactions with cyclosporin (Part I). Clin Pharmacokinet 1990;19:319–332.
5. Yee G, McGuire T. Pharmacokinetic drug interactions with cyclosporin (Part II). Clin Pharmacokinet 1990;19:400–415.
6. Dresser G, Spence J, Bailey D. Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome p450 3A4 inhibition. Clin Pharmacokinet 2000;38:41–57.
7. Ingle G, Sievers T, Holt C. Sirolimus: Continuing the evolution of transplant immunosuppression. Ann Pharmacother 2000;34:1044–1045.
8. Fireman M, DiMartini A, Armstrong S, et al. Immunosuppressants. Psychsomatics 2004;45:354–360.
9. Gupta S, Bakran A, Johnson R, et al. Cyclosporin–erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989;27:475–481.
10. Doose D, Walker S, Chien S, et al. Levofloxacin does not alter cyclosporine disposition. J Clin Pharmacol 1998;38:90–93.
11. Stamatakis M, Richards J. Interaction between quinupristin/dalfopristin and cyclosporine. Ann Pharmacother 1997;31:576–578.
12. Schulman S, Shaw L, Jabs K, et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. Transplantation 1998;65:1397–1398.
13. Albengres E, Le Louet H, Tillement J. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998;18:83–97.
14. Katz H. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999;141(suppl 56):26–32.
15. Ventkatakrishnan K, von Moltke L, Greenblatt D. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance. Clin Pharmacokinet 2000;38:111–180.
16. Lee C, Gottesman M, Cardarelli C, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998:37:3594–3601.
17. Gutmann H, Fricker G, Drewe J, et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999;56:383–389.
18. Keown P, Laupacis A, Carruthers G, et al. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 1984;38:304–306.
19. Yee G, Lennon T, Gmur D, et al. Age-dependent cyclosporine pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986;40:438–443.
20. Kaijser M, Johnsson C, Zezina L, et al. Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin Transpl 1997;11:577–581.
21. Klintmalm G, Sawe J. High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients. Lancet 1984;1(8379):731.
22. Tugwell P, Ludwin D, Gent M, et al. Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. J Rheumatol 1997;24:1122–1125.
23. Lewis S, McCloskey W. Potentiation of nephrotoxicity by H2-antagonists in patients receiving cyclosporine. Ann Pharmacother 1997;31:363–365.
24. Cohen E, Kramer M, Maoz C, et al. Cyclosporine drug-interaction-induced rhabdomyolysis, a report of two cases in lung transplant recipients. Clin Transplant 200;70:119–122.
25. von Moltke L, Greenblatt D, Schmider J, et al. Metabolism of drugs by cytochrome p450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(suppl 1):33–43.
26. Wright D, Lake K, Bruhn P, et al. Nefazodone and cyclosporine drug–drug interaction. J Heart Lung Transplant 1999;18:913–915.
27. Greene D, Barbhaiya R. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997;33:260–275.
28. Fugh-Berman A. Herb–drug interactions. Lancet 2000;355:134–138.
29. Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251–272.
30. Bailey D, Malcolm J, Arnold O, et al. Grapefruit juice–drug interactions. Br J Clin Pharmacol 1998;46:101–110.
31. Rundles R, Wyngaarden J, Hitchings G, et al. Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout. Trans Assoc Am Physicians 1963;76:126–140.
32. Zimm S, Collins J, O’Neill D, et al. Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983;34:810–817.
33. Szumlanski C, Weinshilboum R. Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456–459.
34. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997;16:267–278.
35. Gossmann J, Kachel H-G, Schoeppe W, et al. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation 1993;56:585–589.
36. Singleton J, Conyers L. Warfarin and azathioprine: An important drug interaction. Am J Med 1992;92:217.
37. Rivier G, Khamashta M, Hughes G. Warfarin and azathioprine: A drug interaction does exist. Am J Med 1992;95:342.
38. Hoffman-La Roche, Inc. CellCept (mycophenolate mofetil capsules). Package insert. 1995.
39. Bullingham R, Nicholls A, Kamm B. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429–455.
40. Hübner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999;21:536–539.
41. Vasquez E, Pollak R. OKT3 therapy increases cyclosporine blood levels. Clin Transplant 1997;11:38–41.